Read twice and referred to the Committee on Finance.
The bill (Patients Before Middlemen Act) tightens Medicare Part D and MA–PD rules to preserve pharmacy access and require PBM accountability. It mandates any-willing-pharmacy participation, defines and reports on “essential retail pharmacies,” creates an allegation/enforcement process, requires detailed PBM transparency reporting and audit rights, limits PBM remuneration to bona fide service fees (with disgorgement), and extends provisions to MA–PD plans.
Progressives emphasize patient access and curbing PBM capture
Relative to its intended legislative type, this bill is a substantive statutory reform that is carefully specified, with detailed operational mechanisms, definitions, deadlines, reporting templates, and enforcement authorities.
The bill (Patients Before Middlemen Act) tightens Medicare Part D and MA–PD rules to preserve pharmacy access and require PBM accountability.
It mandates any-willing-pharmacy participation, defines and reports on “essential retail pharmacies,” creates an allegation/enforcement process, requires detailed PBM transparency reporting and audit rights, limits PBM remuneration to bona fide service fees (with disgorgement), and extends provisions to MA–PD plans.
Many implementation details are delegated to the HHS Secretary with deadlines for standards and machine-readable reporting formats.
Targeted but substantial regulatory overhaul of PBMs with strong industry opposition and complex implementation reduces near-term enactment odds despite some bipartisan sympathy.
Relative to its intended legislative type, this bill is a substantive statutory reform that is carefully specified, with detailed operational mechanisms, definitions, deadlines, reporting templates, and enforcement authorities. It integrates closely with existing statutory provisions and builds in numerous accountability and anti-abuse features.
Progressives emphasize patient access and curbing PBM capture
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize patient access and curbing PBM capture
Likely broadly supportive.
The bill increases transparency, prevents PBM practices that can squeeze independent and essential pharmacies, and strengthens enforcement and anti-retaliation protections for pharmacies.
Cautiously favorable but pragmatic.
Recognizes benefits for access and transparency, while worried about implementation details, administrative burden, and possible unintended cost shifts.
Wants careful rulemaking and fiscal analysis.
Likely opposed or skeptical.
Views the bill as heavy federal intervention into private contracts and PBM-market arrangements, adding compliance costs and risking disruption of negotiated discounts that lower consumer costs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted but substantial regulatory overhaul of PBMs with strong industry opposition and complex implementation reduces near-term enactment odds despite some bipartisan sympathy.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize patient access and curbing PBM capture
Targeted but substantial regulatory overhaul of PBMs with strong industry opposition and complex implementation reduces near-term enactment…
Relative to its intended legislative type, this bill is a substantive statutory reform that is carefully specified, with detailed operational mechanisms, definitions, deadlines, reporting templates, and enforcement auth…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.